MusclePharm adds Dr. Richard Ogden to board

Monday, April 11, 2011 12:37 PM

MusclePharm, a Nevada corporation, a U.S. nutritional supplement company, will add Richard Ogden, PhD, to its medical advisory board.

Ogden is the co-founder of RORR,a medical, scientific consulting and educational company focused on viral infectious diseases, including HIV, and the incorporation of strategic planning for clinical research programs and product development in the antiviral and oncology therapeutic areas. 

Prior to his tenure at RORR, Ogden spent considerable time in a variety of roles at Agouron Pharmaceuticals, before it was acquired by Pfizer. Among his roles were senior scientist, group leader in medicinal chemistry, and director of scientific development.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs